Critics knock JAMA study linking testosterone drugs to cardio risks

Carly Helfand

A the FDA has cited as a reason to investigate the cardiovascular safety of has come under heavy fire from . Physicians and researchers are calling for the November paper's retraction, citing at least two corrections that they say compromise its credibility.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS